cell therapy alpha-sarcoglycan null dystrophic mice intra-arterial delivery mesoangioblasts 
preclinical clinical trials muscular dystrophies met modest success mainly inefficient delivery viral vectors donor cells dystrophic muscles report intra-arterial delivery wildtype mesoangioblasts class vessel-associated stem cells corrects morphologically functionally dystrophic phenotype virtually downstream muscles adult immunocompetent alpha-sarcoglycan alpha-sg null mice model organism limb-girdle muscular dystrophy mesoangioblasts isolated juvenile dystrophic mice transduced lentiviral vector expressing alpha-sg injected femoral artery dystrophic mice reconstituted skeletal muscle manner similar seen wild-type cells success protocol mainly due widespread distribution donor stem cells capillary network distinct advantage strategy previous approaches 
